Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

186.94 +3.81 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186,819
Open 186.64
Bid (Size) 185.00 (8)
Ask (Size) 195.98 (1)
Prev. Close 183.13
Today's Range 183.97 - 189.15
52wk Range 156.56 - 280.62
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
-17.51%
-17.51%
1 Month
+0.35%
+0.35%
3 Month
-9.93%
-9.93%
6 Month
-16.35%
-16.35%
1 Year
-2.44%
-2.44%

More News

Read More
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Via Talk Markets
Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
Via Benzinga
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
7 Biotech Stocks to Buy for Big-Time Gains
Via InvestorPlace
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Via Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Via Talk Markets
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data
Via Benzinga
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
From BeiGene
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Via Talk Markets
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Via Benzinga
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.